论文部分内容阅读
近年有研究发现,人类免疫缺陷病毒(HIV)不进展者体内一种名为抗-R7V的抗体含量很高,并且临床资料显示抗-R7V对HIV感染者具有一定的保护作用,使病情进展延缓或长期停留在无症状期,可以作为疾病进展的一个标志,为人们希望通过自身机体免疫控制HIV感染带来了曙光。对这类患者的研究有利于进一步阐明影响病毒复制的因素,也有助于制定治疗HIV/AIDS患者的新方案。含有R7V肽的酶联免疫吸附试验(ELISA)可以检测到HIV感染者体内的抗-R7V,与CD4计数和病毒载量联合应用,有助于医生决定治疗开始的时机。
In recent years, studies have found that human immunodeficiency virus (HIV) non-progrester in vivo called anti-R7V antibody content is high, and clinical data show that anti-R7V of HIV-infected patients have a certain degree of protection, so that the progress of the disease is delayed Or long-term stay in the asymptomatic period, can be used as a sign of disease progression, people hope that through their own body immune control of HIV infection has brought the dawn. Research on these patients will help further elucidate the factors that affect viral replication and help develop new options for treating HIV / AIDS patients. Enzyme-linked immunosorbent assay (ELISA) with R7V peptide detects anti-R7V in HIV-infected individuals and is combined with CD4 counts and viral load to help physicians decide when to start treatment.